Farxiga (Dapagliflozin) Cost in Georgia: 2026 Prices, Insurance, and Savings Options

What Does Farxiga Actually Cost at Georgia Pharmacies in 2026?

The manufacturer list price for Farxiga (dapagliflozin) set by AstraZeneca is approximately $620 per month for a 30-day supply of 10 mg tablets. This price holds relatively consistent across Georgia retail chains including CVS, Walgreens, and Kroger pharmacy locations. Without insurance or discount programs, most Georgia residents will pay close to this full amount.

That $620 figure represents the wholesale acquisition cost (WAC) passed through to retail. Individual pharmacies may mark up slightly, but competitive pressure in metro Atlanta, Savannah, Augusta, and other Georgia markets keeps cash-pay prices within a narrow band. Some independent pharmacies in rural Georgia counties may charge marginally more due to lower prescription volume and higher per-unit distribution costs.

Pharmacy benefit managers (PBMs) negotiate rebates that bring net costs down for insured patients, but those savings rarely appear on the pharmacy receipt for uninsured buyers. The gap between what AstraZeneca receives after rebates and what a cash-pay patient sees at the counter remains one of the most frustrating realities of SGLT2 inhibitor pricing. Dapagliflozin has been on the U.S. market since its FDA approval in January 2014 for type 2 diabetes, with subsequent label expansions for heart failure (2020) and chronic kidney disease (2021) [1].

For context on clinical value at this price point: the DAPA-HF trial (N=4,744) demonstrated that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% compared with placebo (HR 0.74 to 95% CI 0.65 to 0.85, P<0.001) over a median 18.2 months of follow-up [2]. That efficacy profile makes access a clinical priority, not just a financial question.

Does Georgia Medicaid Cover Farxiga?

Georgia Medicaid covers Farxiga for heart failure and chronic kidney disease indications but does not currently list it as a covered benefit for type 2 diabetes as the sole diagnosis. This distinction matters. A Georgia Medicaid enrollee with T2D alone will face a prior authorization denial, while an enrollee with T2D plus heart failure or CKD stage 3 or higher may gain approval.

Georgia's Medicaid preferred drug list (PDL) reflects the state's cost-containment approach to newer branded agents. SGLT2 inhibitors as a class carry significant per-member-per-month costs, and Georgia has opted to restrict coverage to the indications where clinical trial data shows the strongest mortality and hospitalization benefits. The DAPA-CKD trial (N=4,304) showed a 39% reduction in the composite of sustained eGFR decline of 50% or more, end-stage kidney disease, or renal or cardiovascular death (HR 0.61 to 95% CI 0.51 to 0.72, P<0.001) [3]. That result applies regardless of diabetes status, which is why the CKD indication receives coverage priority.

The American Diabetes Association's 2024 Standards of Care state: "For patients with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, an SGLT2 inhibitor with demonstrated benefit is recommended independent of A1C" [4]. Georgia Medicaid's restriction to HF and CKD indications partially aligns with this guidance, though it excludes the ASCVD indication and T2D-only glycemic use.

If you carry a Georgia Medicaid plan and have been prescribed Farxiga for type 2 diabetes only, your prescriber can submit a prior authorization with supporting documentation of concurrent heart failure or CKD. ICD-10 codes I50.x (heart failure) or N18.x (CKD) on the claim will trigger a different review pathway than E11.x (T2D) alone.

Georgia Insurance Coverage Beyond Medicaid

Commercial insurance plans sold in Georgia through the state exchange (via healthcare.gov) and employer-sponsored plans each maintain their own formulary decisions for Farxiga. Coverage varies widely. Here is what to expect from the major carriers operating in Georgia in 2026.

Anthem Blue Cross Blue Shield Georgia typically places Farxiga on Tier 3 (preferred brand) with a copay ranging from $35 to $75 after deductible, depending on the specific plan. Some Anthem plans require step therapy through metformin first for T2D indications.

Ambetter (Centene) exchange plans in Georgia often classify SGLT2 inhibitors on Tier 3 or Tier 4 (non-preferred brand), with copays from $50 to $150 or coinsurance of 25% to 40%. Prior authorization is common.

Kaiser Permanente Georgia covers dapagliflozin on its formulary with typical specialist-tier copays. Kaiser's integrated model means the prescribing physician and pharmacy benefit operate within the same system, which can speed prior authorization turnaround.

UnitedHealthcare plans in Georgia generally cover Farxiga at Tier 3 with prior authorization required for the T2D indication. The HF and CKD indications may receive expedited approval.

Dr. Mikhail Kosiborod, a cardiologist at Saint Luke's Mid America Heart Institute who led multiple SGLT2 inhibitor analyses, has noted: "The evidence for SGLT2 inhibitors in heart failure is so strong that restricting access based on formulary tier creates a gap between guideline recommendations and real-world treatment" [5]. This observation applies directly to Georgia patients navigating commercial plan restrictions.

For any Georgia commercial plan, the appeals process involves a two-step sequence: first, your prescriber submits a prior authorization with clinical justification. If denied, a peer-to-peer review between your prescriber and the plan's medical director follows. Citing specific trial evidence (DAPA-HF, DAPA-CKD, DECLARE-TIMI 58) in the appeal letter increases approval rates.

The AstraZeneca Savings Card: How It Works in Georgia

AstraZeneca offers a manufacturer copay savings card for Farxiga that can reduce out-of-pocket costs to $0 per month for eligible patients. The card is valid at all Georgia pharmacies that accept commercial insurance. Patients must carry commercial (private) insurance to qualify. Medicare, Medicaid, Tricare, and other government-funded plan enrollees are excluded by federal anti-kickback statute requirements.

Eligibility rules are straightforward. You need a valid Farxiga prescription, commercial insurance that covers at least part of the cost, and U.S. residency. The card covers up to a set annual maximum (typically $3,600 per calendar year, though AstraZeneca adjusts this periodically). For a patient with a $75 monthly copay, the savings card covers the full $75, resulting in $0 at the pharmacy counter. For a patient with a $200 coinsurance obligation, the card covers up to that amount until the annual cap is reached.

Activation takes about five minutes online or by phone. The card generates a BIN, PCN, and group number that the pharmacist enters as secondary coverage at the point of sale. Most Georgia pharmacies process it without issue, though some independent pharmacies may need to call the processor to manually adjudicate.

One important detail: savings card payments do not count toward your insurance plan's deductible or out-of-pocket maximum under most accumulator adjustment programs. Several Georgia commercial plans (notably some Anthem and UnitedHealthcare offerings) have adopted accumulator or maximizer programs that exclude manufacturer copay assistance from deductible calculations. Check your specific plan's benefit design before assuming the savings card accelerates your deductible spend.

Is Compounded Dapagliflozin Legal in Georgia?

Yes. Compounded dapagliflozin is legal in Georgia when prepared by a licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Georgia follows federal FDA compounding guidelines under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits pharmacies to compound medications that are commercially available if certain conditions are met [6].

A 503A pharmacy compounds medications for individual patients based on a prescriber's order. The pharmacy must hold a valid Georgia Board of Pharmacy license. The compounded product cannot be an exact copy of the commercially available drug in the same dosage form and strength, so compounding pharmacies typically formulate dapagliflozin in a different concentration, as a liquid suspension, or in a capsule form rather than replicating AstraZeneca's exact 5 mg or 10 mg tablet.

Cost differences are substantial. Compounded dapagliflozin from a Georgia-licensed 503A pharmacy typically costs between $30 and $90 per month, compared with $620 for the brand product. The trade-off involves less rigorous bioequivalence testing than the FDA requires of generic manufacturers. Compounded products are not FDA-approved, do not undergo dissolution testing, and may have batch-to-batch variability in active ingredient content.

The DECLARE-TIMI 58 trial (N=17,160) established dapagliflozin's cardiovascular safety profile using the branded formulation [7]. No large-scale outcomes trial has been conducted with compounded dapagliflozin. For patients choosing the compounded route, periodic monitoring of fasting glucose, A1C, and (for CKD patients) eGFR and urine albumin-to-creatinine ratio is especially important to confirm therapeutic response.

Several Georgia-based 503A compounding pharmacies serve patients statewide, including operations in Atlanta, Marietta, Savannah, and Athens. Telehealth prescribers licensed in Georgia can send prescriptions directly to these pharmacies.

Telehealth Access to Farxiga in Georgia

Georgia permits telehealth prescribing of Farxiga. This applies to both brand-name and compounded formulations. A prescriber licensed in the state of Georgia can evaluate a patient via synchronous video visit and issue a prescription for dapagliflozin without requiring an in-person visit first.

Georgia's telehealth parity law (O.C.G.A. 33-24-56.4) requires commercial insurers to cover telehealth services on the same basis as in-person visits. This means a telehealth consultation that results in a Farxiga prescription should be covered at the same copay and coinsurance level as an office visit. The prescribing itself is not restricted by the modality of the encounter.

For patients in rural Georgia counties where endocrinology, cardiology, or nephrology specialists are scarce, telehealth removes a significant access barrier. Georgia has 159 counties, and many outside the Atlanta, Augusta, and Savannah metropolitan areas have limited specialty coverage. A patient in Valdosta or Waycross can consult with an Atlanta-based cardiologist via video and receive a Farxiga prescription sent electronically to a local pharmacy or a statewide compounding pharmacy.

Telehealth platforms that operate in Georgia (including HealthRX) can prescribe dapagliflozin after confirming the clinical indication, reviewing relevant lab work (A1C, serum creatinine, eGFR, potassium, blood pressure), and assessing for contraindications. SGLT2 inhibitors require baseline renal function assessment: dapagliflozin should not be initiated for the glycemic indication when eGFR is below 25 mL/min/1.73 m², per current FDA labeling [1].

Discount Programs and Additional Savings Strategies

Beyond the AstraZeneca savings card, several discount pathways exist for Georgia residents filling Farxiga prescriptions.

GoodRx, RxSaver, and similar discount card platforms aggregate pharmacy pricing and offer coupons that can reduce the cash price of brand Farxiga by 10 to 40% at select Georgia locations. These work best for uninsured patients or those whose insurance does not cover the drug. Prices fluctuate weekly, so checking multiple platforms before filling is worth the effort.

AstraZeneca's AZ&Me patient assistance program provides free Farxiga to qualifying uninsured or underinsured patients with household incomes at or below 400% of the federal poverty level. The application requires income documentation and a prescriber signature. Approval typically takes two to four weeks, and the medication ships directly to the patient's home or prescriber's office.

340B program pharmacies in Georgia (primarily associated with federally qualified health centers, disproportionate share hospitals, and Ryan White clinics) purchase Farxiga at significantly reduced prices and may pass savings to qualifying patients. Georgia has over 30 FQHC systems with 340B eligibility. Patients treated at these facilities for diabetes, heart failure, or CKD can ask whether 340B pricing applies to their Farxiga prescription.

Medicare Part D covers Farxiga, and the Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective 2025) means Medicare beneficiaries in Georgia will pay no more than $2,000 total for all covered Part D drugs in a calendar year [8]. For a patient whose only expensive medication is Farxiga, this cap is reached in approximately three to four months of fills, after which the plan covers the remainder at no additional cost for the rest of the year.

Clinical Indications and Why Cost Matters for Georgia Patients

Dapagliflozin's three FDA-approved indications each carry different urgency profiles that affect how aggressively patients and prescribers should pursue access.

For heart failure with reduced ejection fraction (HFrEF), the DAPA-HF data showed a number needed to treat (NNT) of 21 over 18.2 months to prevent one primary outcome event [2]. That means for every 21 Georgia patients started on dapagliflozin for HFrEF, one will avoid a heart failure hospitalization or cardiovascular death that would have occurred on standard therapy alone. Heart failure hospitalizations in Georgia average $15,000 to $25,000 per admission. Even at $620 per month ($7,440 annually), the drug pays for itself in averted hospitalizations within the first two years for a typical HFrEF population.

For CKD, the stakes involve progression to dialysis. Georgia ranks among the top ten U.S. states for end-stage kidney disease incidence, driven by high prevalence of diabetes and hypertension. Dialysis costs Medicare approximately $90,000 per patient per year. The DAPA-CKD trial's 39% relative risk reduction in kidney failure progression [3] makes dapagliflozin one of the most cost-effective interventions available to slow CKD in Georgia's population.

For type 2 diabetes as a glycemic agent, dapagliflozin reduces A1C by approximately 0.5 to 0.7 percentage points as monotherapy and provides 2 to 3 kg of weight loss [1]. While effective, the glycemic benefit alone is harder to justify at $620 per month when metformin (approximately $4 to $10 per month) remains the first-line standard. The cardiovascular and renal co-benefits are what make SGLT2 inhibitors worth pursuing despite the price.

The 2023 KDIGO guideline for diabetes management in CKD states: "SGLT2 inhibitors are recommended for patients with type 2 diabetes and CKD with eGFR ≥20 mL/min/1.73 m²" [9]. Georgia clinicians following this guideline should consider dapagliflozin a first-priority add-on to metformin for any patient meeting these criteria.

Generic Dapagliflozin: Georgia Timeline

AstraZeneca's key U.S. patents on dapagliflozin are expected to face generic competition in the 2025 to 2027 timeframe, depending on litigation outcomes and FDA approval timelines for pending abbreviated new drug applications (ANDAs). As of mid-2026, no FDA-approved generic dapagliflozin tablet is available in Georgia pharmacies.

When generics do arrive, pricing typically drops 80 to 90% within the first 18 months of multi-source generic availability. A generic dapagliflozin 10 mg tablet could reasonably be expected to cost $20 to $60 per month at Georgia retail pharmacies once three or more generic manufacturers enter the market. Until then, the savings strategies outlined above remain the primary tools for reducing out-of-pocket burden.

Patients currently using compounded dapagliflozin may want to transition to the FDA-approved generic once available, given the tighter quality controls and bioequivalence requirements that generic manufacturers must meet.